What Akcea Shareholders Get in the Ionis Buyout
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Chris Lange
6 months ago

Why This Cardiovascular Disease Study Could Be Huge
Akcea Therapeutics and Ionis Pharmaceuticals each made handy gains on Wednesday after the firms reported midstage results for their cardiovascular disease study.
Chris Lange
1 year ago
Last Updated: 1 year ago

Novartis Finally Comes Through With Its Acquisition of Medicines Co
Medicines Co shares shot up on Monday after it was reported that Novartis will be acquiring the firm. The transaction was unanimously approved by the boards of directors of both companies.
Chris Lange
1 year ago
Last Updated: 1 year ago

Will Medicines Co Be the Next Target of Novartis?
Medicines shares shot up on Tuesday after it was reported that Novartis might be eyeing this company as its newest acquisition.
Chris Lange
1 year ago
Last Updated: 1 year ago

The Best Biotech ETFs to Buy Ahead of ASCO
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
Chris Lange
1 year ago
Last Updated: 1 year ago

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Jon C. Ogg
1 year ago
Last Updated: 1 year ago

Meet Ionis Pharma's Newest Collaboration
Ionis Pharmaceuticals shares were relatively flat on Wednesday after the company announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases.
Chris Lange
2 years ago
Last Updated: 1 year ago

Akcea Stumbles Over Newest Board Addition
Akcea Therapeutics shares pulled back on Monday after the company announced a big change to its board of directors.
Chris Lange
2 years ago
Last Updated: 1 year ago

Akcea and Ionis Pharma Win Big in Midstage Cardiovascular Disease Study
Akcea and Ionis Pharmaceuticals shares made a solid gain on Monday after the companies announced positive top-line data for a midstage trial in patients with established cardiovascular disease and...
Chris Lange
2 years ago
Last Updated: 1 year ago

Why Akcea and Ionis Are Getting Crushed
Akcea and Ionis were each crushed on Tuesday after the firms announced that they received a Complete Response Letter from the FDA.
Chris Lange
2 years ago
Last Updated: 1 year ago

Akcea Therapeutics Jumps on European Marketing Approval
Akcea Therapeutics shares saw a nice bump on Wednesday after the company announced in conjunction with Ionis Pharmaceuticals that they had received a marketing authorization approval from the...
Chris Lange
2 years ago
Last Updated: 1 year ago

What to Expect From the Newest Biogen Collaboration
Ionis Pharmaceuticals shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen.
Chris Lange
2 years ago
Last Updated: 1 year ago

Akcea Therapeutics Announces Potential Pricing for IPO
Akcea Therapeutics expects to price more than 9 million shares in the range of $12 to $14 apiece in an initial public offering valued up to almost $155 million.
Chris Lange
3 years ago
Last Updated: 1 year ago

Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results
Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy.
Chris Lange
3 years ago
Last Updated: 1 year ago

Akcea Therapeutics Gears Up for IPO
Akcea Therapeutics has amended its filing with the SEC for its initial public offering.
Chris Lange
3 years ago
Last Updated: 1 year ago